Market News & Trends
Deciphera Pharmaceuticals Announces $75-Million Financing
Deciphera Pharmaceuticals recently announced it has closed a $75-million Series B financing led by New Leaf Venture Partners and joined by Deciphera’s existing investors. The…
BIND Therapeutics Announces Pfizer Exercises Option
BIND Therapeutics, Inc. recently announced Pfizer Inc. exercised its option to obtain an exclusive license to develop and commercialize an Accurin drug candidate for the…
Xcelience & Powdersize Add Delta Vita Nano-Milling
Xcelience and Powdersize recently announced the addition of the Netzsch Delta Vitamedia mills, a nanoparticle milling solution, to their arsenal of capabilities. For the first…
Nemera’s Next-Generation Nasal Spray Now in Production
Nemera has invested more than 10 million euros in R&D and manufacturing to launch the only user-independent multi-dose nasal spray system on the market. So…
Oncology Leads Development in Promising Gene Therapy Pipeline
Despite few products having so far reached the market and captured strong revenues, the gene therapy pipeline remains large, with 906 products in active development…
Drug Development & Delivery to Launch Innovation Networking Event
Drug Development & Delivery President & Publisher Ralph Vitaro recently announced that the leading media company will be hosting the inaugural Innovation Networking Summit &…
Dimension Therapeutics Announces FDA Fast Track Designation
Dimension Therapeutics, Inc. recently announced that the US FDA has granted Fast Track designation for the company’s lead product candidate, DTX101, for the treatment of…
West Pharmaceutical Services & Healthprize Technologies Announce Self-Reporting & Barcoding Capabilities for Self-Injection Technology
West Pharmaceutical Services, Inc. and HealthPrize Technologies, LLC, recently announced the completion of the first two phases of their four-phase strategic collaboration. The companies are…
Theravance Biopharma & Mylan Initiate Phase III Program
Theravance Biopharma, Inc. and Mylan N.V. recently announced the initiation of a Phase III program for revefenacin (TD-4208), an investigational long-acting muscarinic antagonist (LAMA) in…
Lpath Initiates First-in-Human Dosing in Phase I Trial
Lpath, Inc. recently announced that the first cohort of six subjects has been dosed in the Phase I clinical trial with Lpathomab. The double-blind, placebo-controlled,…
EMD Millipore Introduces Enhancements to its EMPROVE® Program
EMD Millipore Introduces Enhancements to its EMPROVE® Program EMD Millipore recently introduced enhancements to its industry-leading EMPROVE portfolio of pharmaceutical raw materials. The expanded documentation…
Science-Based Technology Selection & Formulation Development for Oral Bioavailability Enhancement
Capsugel Dosage Form Solutions White Paper Authors: Hywel Williams, Michael Morgen, Eduardo Jule, Jan Vertommen, Hassan Benameur, Dwayne Friesen and David Vodak Introduction The increasing…
Benign Prostatic Hyperplasia Treatment Market Value to Reach Nearly $5 Billion
The value of the global therapeutics market for Benign Prostatic Hyperplasia (BPH) will rise from just over $2 billion in 2014 to approximately $4.9 billion…
US Patent Granted for Use of Genticel’s Antigen Delivery Vectors
Genticel recently announced that a new patent (No. 9,095,537), Therapy of Cancer Based on Targeting Adaptive, Innate and/or Regulatory Component of the Immune Response,…
Oramed Completes Randomization of Over 50% of Patients in Phase IIb Study
Oramed Pharmaceuticals Inc. recently announced that 98 patients have already been enrolled in the company’s Phase IIb study of its oral insulin capsule, ORMD-0801, which…
Lubrizol CDMO Acquisition Significantly Broadens its Capabilities
The Lubrizol Corporation recently announced it has acquired Particle Sciences, a leading contract drug development and manufacturing organization with a comprehensive suite of services for…
Enable Injections Completes its First-In-Human Wearable Injector Pilot Trial
Enable Injections recently announced it has completed its first-in-human pilot trial. The study evaluated dose delivery, injection pain, and ease of use in subcutaneous self-delivery.…
Aragen Bioscience Announces Licensing Agreement for Protein Production Technology
Aragen Bioscience, Inc. recently announced it has entered into an agreement with ProteoNic Biotechnology BV for the commercial use of ProteoNic’s 2G UNic recombinant protein…
FDA Accepts First Digital Medicine New Drug Application
Otsuka Pharmaceutical Co., Ltd. and Proteus Digital Health recently announced the US FDA has determined that the New Drug Application for the combination product of…
Downstream Processing - BioProcess International Conference Pre-Event Podcast Series
Hear talk previews from Recovery & Purification + Analytcal, Quality, and Formulations speakers Characterization of Host-Cell Proteins Using Mass Spectrometry Enables Effective Purification Optimization…
